Trial Profile
SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Alendronic acid
- Indications Calcinosis
- Focus Therapeutic Use
- Acronyms SALTIRE II
- 13 Nov 2023 Results assessing pre-specified secondary analyses of 24-month change in coronary and ascending aorta calcium scores and 12-month change in coronary and aortic 18F-NaF activity ,presented at the American Heart Association Scientific Sessions 2023.
- 29 Aug 2022 Results (n=136) of post-hoc analysis assessing fibro-calcific aortic valve thickening in patients with aortic valve stenosis and its reproducibility, associations with echo parameters of AS severity and disease progression presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
- 29 Apr 2021 Results published in the Circulation